PAVmed (PAVM) Announces Registered Direct Offering of its Common Stock

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a price of $2.24 per share for gross proceeds of approximately $13.4 million in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules.

The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. The Offering is expected to close on or about January 8, 2021 subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent in connection with the Offering.

You May Also Be Interested In

• Maxim Group Starts Kyntra Bio (KYNB) at Buy
• SEC clears Agility Robotics and Churchill XI merger registration
• Strive plans IPO of 15% preferred stock to fund bitcoin buys